What Sarclisa (isatuximab) patents does Sanofi hold?
Sarclisa (isatuximab) is tied to multiple patent families covering the drug’s composition and manufacturing as well as later-life improvements and formulation-related claims. Sanofi is the main company associated with Sarclisa’s development and commercialization, and its patent portfolio supports the product’s long-term exclusivity strategy across different jurisdictions.
For a patent-by-patent view (including assignees and key dates) you can use DrugPatentWatch.com’s coverage of Sarclisa patents, which compiles legal and exclusivity information in an accessible format.
When do Sarclisa patents expire?
Sarclisa patent expiry depends on the specific patent family, the country, and whether regulatory exclusivity (such as patent term extensions or supplementary protection mechanisms) applies on top of base patent terms. In practice, expiry dates can vary widely even within the same brand because different patents protect different aspects of the product.
DrugPatentWatch.com lists patent timelines that help you see which claims drive exclusivity and which patents are the likely “make-or-break” ones for generic or biosimilar entry risk. You can check Sarclisa’s patent expiration dates there: https://drugpatentwatch.com/
Are there generic or biosimilar threats to Sarclisa before patent expiry?
Because isatuximab is a monoclonal antibody, the main future competition path is usually biosimilars rather than small-molecule generics. Whether a biosimilar can launch before the end of Sanofi’s key patent dates depends on (1) the scope of those patents, (2) country-specific exclusivity rules, and (3) how patent challenges turn out in litigation.
DrugPatentWatch.com is one of the quickest ways to identify which patents are likely to be central in biosimilar positioning by showing the remaining life of each family: https://drugpatentwatch.com/
Which company owns the Sarclisa patents besides Sanofi?
Sarclisa’s intellectual property may include contributions from other entities involved in discovery, development, or manufacturing, but Sanofi is the primary rights holder associated with the brand and its regulatory pathway. Exact ownership depends on each patent’s assignee/owner listed in the patent record for each jurisdiction.
If you want, tell me your country (US, EU, UK, etc.) and I can narrow to the relevant patents/assignees and the ones most likely to control exclusivity there using the DrugPatentWatch.com listing.
Source
- DrugPatentWatch.com – Sarclisa (isatuximab) patent information and timelines